Status:
COMPLETED
Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome
Lead Sponsor:
University of Virginia
Conditions:
Cannabinoid Hyperemesis Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study aims to determine if capsaicin cream offers symptomatic relief to patients suffering from Cannabinoid Hyperemesis Syndrome (condition that leads to repeated and severe bouts of vomiting).
Detailed Description
Objectives: The purpose of this study is to determine if capsaicin cream offers symptomatic relief to patients suffering from Cannabinoid Hyperemesis Syndrome. We hypothesize that the use of topical ...
Eligibility Criteria
Inclusion
- At least 18 years old
- Diagnosis of cannabinoid hyperemesis syndrome
Exclusion
- Patients who receive more than 2 anti-emetic therapies prior to screening for enrollment
- Patients who receive haloperidol as an anti-emetic therapy
- Pregnant women
- Prisoners
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04283292
Start Date
December 1 2020
End Date
March 18 2022
Last Update
October 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UVA Health System
Charlottesville, Virginia, United States, 22908